Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies

N. Bettazova, J. Senavova, K. Kupcova, D. Sovilj, A. Rajmonova, L. Andera, K. Svobodova, A. Berkova, Z. Zemanova, L. Daumova, V. Herman, A. Dolníkova, RE. Davis, M. Trneny, P. Klener, O. Havranek

. 2024 ; 8 (20) : 5279-5289. [pub] 20241022

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003833

Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains and PTEN losses. To evaluate the biological and functional consequences of these aberrations in MCL, we have introduced transgenic expression of PIK3CA (PIK3CA UP) and performed knockout/knockdown of PTEN gene (PTEN KO/KD) in 5 MCL cell lines. The modified cell lines were tested for associated phenotypes including dependence on upstream B-cell receptor (BCR) signaling (by an additional BCR knockout). PIK3CA overexpression decreased the dependence of the tested MCL on prosurvival signaling from BCR, decreased levels of oxidative phosphorylation, and increased resistance to 2-deoxy-glucose, a glycolysis inhibitor. Unchanged protein kinase B (AKT) phosphorylation status and unchanged sensitivity to a battery of PI3K inhibitors suggested that PIK3CA gain might affect MCL cells in AKT-independent manner. PTEN KO was associated with a more distinct phenotype: AKT hyperphosphorylation and overactivation, increased resistance to multiple inhibitors (most of the tested PI3K inhibitors, Bruton tyrosine kinase inhibitor ibrutinib, and BCL2 inhibitor venetoclax), increased glycolytic rates with resistance to 2-deoxy-glucose, and significantly decreased dependence on prosurvival BCR signaling. Our results suggest that the frequent aberrations of the PI3K pathway may rewire associated signaling with lower dependence on BCR signaling, better metabolic and hypoxic adaptation, and targeted therapy resistance in MCL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003833
003      
CZ-PrNML
005      
20250206104728.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2024013205 $2 doi
035    __
$a (PubMed)39158100
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bettazova, Nardjas $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0009000542863538
245    10
$a Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies / $c N. Bettazova, J. Senavova, K. Kupcova, D. Sovilj, A. Rajmonova, L. Andera, K. Svobodova, A. Berkova, Z. Zemanova, L. Daumova, V. Herman, A. Dolníkova, RE. Davis, M. Trneny, P. Klener, O. Havranek
520    9_
$a Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains and PTEN losses. To evaluate the biological and functional consequences of these aberrations in MCL, we have introduced transgenic expression of PIK3CA (PIK3CA UP) and performed knockout/knockdown of PTEN gene (PTEN KO/KD) in 5 MCL cell lines. The modified cell lines were tested for associated phenotypes including dependence on upstream B-cell receptor (BCR) signaling (by an additional BCR knockout). PIK3CA overexpression decreased the dependence of the tested MCL on prosurvival signaling from BCR, decreased levels of oxidative phosphorylation, and increased resistance to 2-deoxy-glucose, a glycolysis inhibitor. Unchanged protein kinase B (AKT) phosphorylation status and unchanged sensitivity to a battery of PI3K inhibitors suggested that PIK3CA gain might affect MCL cells in AKT-independent manner. PTEN KO was associated with a more distinct phenotype: AKT hyperphosphorylation and overactivation, increased resistance to multiple inhibitors (most of the tested PI3K inhibitors, Bruton tyrosine kinase inhibitor ibrutinib, and BCL2 inhibitor venetoclax), increased glycolytic rates with resistance to 2-deoxy-glucose, and significantly decreased dependence on prosurvival BCR signaling. Our results suggest that the frequent aberrations of the PI3K pathway may rewire associated signaling with lower dependence on BCR signaling, better metabolic and hypoxic adaptation, and targeted therapy resistance in MCL.
650    12
$a lymfom z plášťových buněk $x farmakoterapie $x genetika $x metabolismus $7 D020522
650    12
$a fosfohydroláza PTEN $x metabolismus $x genetika $7 D051059
650    _2
$a lidé $7 D006801
650    12
$a fosfatidylinositol-3-kinasy třídy I $x genetika $x metabolismus $7 D058534
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
650    _2
$a signální transdukce $7 D015398
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a protoonkogenní proteiny c-akt $x metabolismus $7 D051057
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a receptory antigenů B-buněk $x metabolismus $7 D011947
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Senavova, Jana $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $u BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000156614456
700    1_
$a Kupcova, Kristyna $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $u BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000249139877
700    1_
$a Sovilj, Dana $u Institute of Biotechnology BIOCEV, Czech Academy of Sciences, Prague, Czech Republic $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000287015912
700    1_
$a Rajmonova, Anezka $u BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0009000746294832
700    1_
$a Andera, Ladislav $u Institute of Biotechnology BIOCEV, Czech Academy of Sciences, Prague, Czech Republic $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Svobodova, Karla $u Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000167571332 $7 xx0276416
700    1_
$a Berkova, Adela $u Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Zemanova, Zuzana $u Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Daumova, Lenka $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Herman, Vaclav $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $u BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000203167290
700    1_
$a Dolníkova, Alexandra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000259826523
700    1_
$a Davis, R Eric $u Department of Lymphoma and Myeloma, The UT MD Anderson Cancer Center, Houston, TX $1 https://orcid.org/0000000191972523
700    1_
$a Trneny, Marek $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000177869378 $7 xx0105452
700    1_
$a Havranek, Ondrej $u First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic $u BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000158263557 $7 xx0128548
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 20 (2024), s. 5279-5289
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39158100 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104724 $b ABA008
999    __
$a ok $b bmc $g 2263537 $s 1239840
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 20 $d 5279-5289 $e 20241022 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace